News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
MiNK Therapeutics announced results for the fourth quarter and year-end of 2023
Photo: minkherapeutics.com
Mar 24, 2024, 13:10

MiNK Therapeutics announced results for the fourth quarter and year-end of 2023

MiNK Therapeutics shared on their LinkedIn page:

“Today MiNK announced results for the fourth quarter and year-end of 2023. Our year was marked by progress across our clinical programs, manufacturing capabilities, and research team, which continue to solidify MiNK’s leadership in the field of iNKT cell therapy.

Read more about the results and our plans for 2024 here.”

Image preview

Source: MiNK Therapeutics/LinkedIn

cancer Cell Therapy clinical progress iNKT cell therapy leadership team Medical Advancements MiNK Therapeutics OncoDaily Oncology research excellence
Special Coverage
Blog
Jan 20, 2025, 12:16
Rita A. Sakr: Honored to present dear breast cancer survivors at SABCS24
Blog
Jan 20, 2025, 12:11
Catharine Young: Real progress doesn’t happen in isolation
Blog
Jan 20, 2025, 11:28
Fernanda Rivera's Journey as the first Mexican RadOnc Resident to receive the ASCO IDEA Award
Blog
Jan 20, 2025, 04:32
Bevacizumab and carboplatin-pemetrexed chemotherapy with/out atezolizumab for advanced pleural mesothelioma
Blog
Jan 20, 2025, 04:29
Katsuaki Maehara: Lung EGFR mutations catalog
Opinion
Jan 20, 2025, 04:25
Elisabetta Bonzano: The identification and validation of patient-specific vulnerabilities
Blog
Jan 20, 2025, 04:21
Robin Zon: Behind every diagnosis, test, approval/ disapproval and outcome is a patient and their family
Insight
Jan 20, 2025, 04:14
Laura Bukavina discusses a paper on BCG treatment for patients with urothelial carcinoma of the prostatic urethra
Insight
Jan 20, 2025, 04:00
FDA approved datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
Career
Jan 20, 2025, 03:10
Lawrence “Larry” Deist Appointed to Board of Directors at Rally Foundation for Childhood Cancer Research
Blog
Jan 20, 2025, 02:54
Drew Moghanaki: A new medical oncology position at the VA Medical Center in Long Beach
Science
Jan 20, 2025, 02:44
Assessment of fitness for bleomycin use and management of bleomycin pulmonary toxicity in patients with classical HL